Yusuke Ando

Dr. Yusuke Ando


Research Focus & Metrics

Academic Career Length

72Years (1955-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2009 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
TMT. Maruyama
T. Maruyama
YSYoichi Shiota
Yoichi Shiota
TNTakayuki Nozaki
Takayuki Nozaki
KOK. Ohta
K. Ohta
NTN. Toda
N. Toda
YSY. Suzuki
Y. Suzuki

25 December 2013 in JAMA
Verified
Journal Article
Open access
PDF file
JBJohn L. Berk
John L. Berk
OSOle B. Suhr
Ole B. Suhr
LOLaura Obici
Laura Obici
YSYoshiki Sekijima
Yoshiki Sekijima
SZSteven R. Zeldenrust
Steven R. Zeldenrust
FCfor the Diflunisal Trial Consortium
for the Diflunisal Trial Consortium
Hereditary transthyretin amyloidosis (ATTR) is a lethal, autosomal dominant genetic disease caused by the aggregation of variant and wild-type transthyretin (TTR), a thyroxine transport protein predominantly produced by the liver.1,2 More than 100 different mutations in the TTR gene destabilize its tetrameric structure, promoting TTR dissociation and misassembly into oligomeric aggregates including amyloid fibrils.3,4 The process of TTR amyloidogenesis produces a spectrum of debilitating disease ranging from pure polyneuropathy (transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) to selective heart involvement.5,6 In ATTR-FAP, small- and large-fiber injury induce sensory and autonomic deficits accompanied by motor weakness in a length-dependent fashion, mimicking manifestations of diabetic polyneuropathy. Untreated, patients exhibit progressive neurological deficits, dying 10 to 15 years after disease presentation.7 Fewer than 10 000 people are estimated to be clinically affected worldwide.8

1 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
YAYusuke Ando
Yusuke Ando
TCTeresa Coelho
Teresa Coelho
JBJohn L Berk
John L Berk
MCMárcia Waddington Cruz
Márcia Waddington Cruz
BEBo-Göran Ericzon
Bo-Göran Ericzon
FSFabrizio Salvi
Fabrizio Salvi
Transthyretin amyloidosis is a progressive and eventually fatal disease primarily characterized by sensory, motor, and autonomic neuropathy and/or cardiomyopathy. Given its phenotypic unpredictability and variability, transthyretin amyloidosis can be difficult to recognize and manage. Misdiagnosis is common, and patients may wait several years before accurate diagnosis, risking additional significant irreversible deterioration. This article aims to help physicians better understand transthyretin amyloidosis—and, specifically, familial amyloidotic polyneuropathy—so they can recognize and manage the disease more easily and discuss it with their patients. We provide guidance on making a definitive diagnosis, explain methods for disease staging and evaluation of disease progression, and discuss symptom mitigation and treatment strategies, including liver transplant and several pharmacotherapies that have shown promise in clinical trials.

1 September 2009 in Cell Metabolism
Verified
Journal Article
Closed access
MTMitsuhisa Tabata
Mitsuhisa Tabata
TKTsuyoshi Kadomatsu
Tsuyoshi Kadomatsu
SFShigetomo Fukuhara
Shigetomo Fukuhara
KMKeishi Miyata
Keishi Miyata
YIYasuhiro Ito
Yasuhiro Ito
YOYuichi Oike
Yuichi Oike

1 July 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
YAYusuke Ando
Yusuke Ando
MNMasaaki Nakamura
Masaaki Nakamura
SAShukuro Araki
Shukuro Araki
Transthyretin-related familial amyloidotic polyneuropathy (FAP) is a fatal hereditary amyloidosis. Until 20 years ago, FAP was thought to be restricted to endemic occurrence in certain areas. However, owing to progress in biochemical and molecular genetic analyses, FAP is now believed to occur worldwide. As of today, reports of about 100 different points of single or double mutations, or a deletion in the transthyretin gene, have been published, and several different phenotypes of FAP have been documented, even for the same mutation in the transthyretin gene. We present herein the current clinicopathological, biochemical, molecular genetic, and epidemiological aspects of transthyretin-related FAP, and we introduce a new diagnostic procedure for the disease.

16 March 2011 in Physical Review Letters
Verified
Journal Article
Closed access
PDF file
SMShigemi Mizukami
Shigemi Mizukami
FWF. Wu
F. Wu
ASA. Sakuma
A. Sakuma
JWJ. Walowski
J. Walowski
DWD. Watanabe
D. Watanabe
TMT. Miyazaki
T. Miyazaki
Spin precession with frequencies up to 280 GHz is observed in Mn3−δGa alloy films with a perpendicular magnetic anisotropy constant Ku∼15  M erg/cm3. The damping constant α, characterizing macroscopic spin relaxation and being a key factor in spin-transfer-torque systems, is not larger than 0.008 (0.015) for the δ=1.46 (0.88) film. Those are about one-tenth of α values for known materials with large Ku. First-principles calculations well describe both low α and large Ku for these alloys.